Physician
Prime Healthcare Services Landmark LLC
Prime Healthcare Services Landmark LLC was paid $1.35M by Medicaid between Jun 2018 and Dec 2024, across 75 billing codes. Its largest line is 99283, emergency room visit (moderate) — 10% of everything it billed.
33Billing provider infoPRIME HEALTHCARE SERVICES LANDMARK LLC
WOONSOCKET, RI 02895
WOONSOCKET, RI 02895
33aNPI1457772543assigned 12/17/2013
33bProvider typeFamily Medicine Physician
28Total paid$1.35M
24GClaims14,752
24DCodes billed75
24AFirst – last monthJun 2018 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in Rhode Island
Rank by total paid#2 of 220
Median peer was paid$33K
This provider vs. median40×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 6,195 | $589K | |
| 2019 | 4,336 | $447K | |
| 2020 | 1,851 | $182K | |
| 2022 | 527 | $28K | |
| 2023 | 879 | $48K | |
| 2024incomplete | 964 | $54K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 586 | 569 | $138K |
| 71046 | Radiologic examination, chest; 2 views | 9.3% | 876 | 846 | $125K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 6.9% | 342 | 293 | $93K |
| 80053 | Comprehensive metabolic panel | 5.5% | 691 | 626 | $74K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 5.0% | 1,677 | 1,513 | $67K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.9% | 1,356 | 834 | $66K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 4.3% | 413 | 409 | $58K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 4.3% | 1,222 | 1,155 | $58K |
| 59025 | Fetal non-stress test | 4.0% | 194 | 152 | $54K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 4.0% | 165 | 134 | $53K |
| 87070 | 3.4% | 926 | 880 | $46K | |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.3% | 846 | 649 | $45K |
63 more codes
| 84443 | Thyroid stimulating hormone (TSH) | 2.8% | 360 | $38K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.7% | 430 | $36K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.7% | 429 | $36K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 2.6% | 106 | $35K |
| 73630 | 2.4% | 214 | $33K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.1% | 450 | $28K |
| 73610 | 1.7% | 149 | $23K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.1% | 60 | $15K |
| 76830 | Ultrasound, transvaginal | 1.1% | 52 | $15K |
| 99204 | Doctor's office visit, new patient (more involved) | 1.0% | 143 | $14K |
| 80061 | Lipid panel | <1% | 152 | $13K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 106 | $13K |
| 76801 | <1% | 42 | $12K | |
| 99284 | Emergency room visit (serious) | <1% | 68 | $12K |
| 73130 | <1% | 76 | $11K | |
| 87186 | <1% | 188 | $10K | |
| 81001 | <1% | 263 | $8K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 173 | $8K |
| 86900 | <1% | 81 | $8K | |
| 99285 | Emergency room visit (most serious) | <1% | 63 | $8K |
| 80076 | <1% | 104 | $7K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 45 | $6K |
| 86850 | <1% | 67 | $6K | |
| 87660 | <1% | 83 | $5K | |
| 87510 | <1% | 83 | $5K | |
| 87480 | <1% | 83 | $5K | |
| 88142 | <1% | 78 | $5K | |
| 86901 | <1% | 81 | $4K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 59 | $4K |
| 87184 | <1% | 114 | $4K | |
| 76536 | <1% | 12 | $3K | |
| 73140 | <1% | 26 | $3K | |
| 73030 | <1% | 28 | $3K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 76 | $3K |
| 84439 | <1% | 41 | $3K | |
| 86703 | <1% | 78 | $2K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 12 | $2K |
| 73110 | <1% | 14 | $2K | |
| 86803 | <1% | 28 | $2K | |
| 74019 | <1% | 12 | $2K | |
| 83690 | <1% | 106 | $2K | |
| 72110 | <1% | 12 | $2K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 111 | $1K |
| 85027 | <1% | 41 | $1K | |
| 85610 | <1% | 67 | $1K | |
| 86592 | <1% | 43 | $1K | |
| 86618 | <1% | 14 | $1K | |
| 87806 | <1% | 12 | $1K | |
| 87205 | <1% | 41 | $968.83 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 13 | $934.52 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 13 | $878.27 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 16 | $794.88 |
| 84484 | <1% | 56 | $770.92 | |
| 81003 | <1% | 40 | $750.95 | |
| 87081 | <1% | 16 | $729.80 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 13 | $619.08 |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 18 | $614.96 |
| 85007 | <1% | 27 | $497.42 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 17 | $147.83 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 13 | $142.79 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 15 | $28.98 |
| 71045 | Radiologic examination, chest; single view | <1% | 13 | $10.77 |
| 3008F | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialVIENS, STACY (PRACTICE ADMINISTRATOR)
Parent organizationPRIME HEALTHCARE SERVICES LANDMARK LLC
| Provider | Location | Paid |
|---|---|---|
| Prime Healthcare Services Landmark LLC | Woonsocket, RI | $233K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.